#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16016	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2062	768.8	0	.	n	.	0	C207T	SNP	207	207	C	438	438	T	847	T,C	598,184	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16016	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2062	768.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1415	1415	C	926	C	866	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29400	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3618	810.0	0	.	n	.	0	T695C	SNP	695	695	T	1081	1081	C	919	C	856	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29400	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3618	810.0	0	.	n	.	0	A1638G	SNP	1638	1638	A	2024	2024	G	998	G,A	935,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29400	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3618	810.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2357	2357	C	919	C	844	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29400	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3618	810.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2431	2431	A	896	A	846	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29400	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3618	810.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2983	2983	C	903	C	851	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2214	folP	855	855	100.0	folP.l15.c4.ctg.1	1473	149.6	1	SNP	p	R229S	1	.	.	685	687	AGC	955	957	AGC	227;226;227	A;G;C,A	212;212;211,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5858	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3437	170.1	1	SNP	p	S91F	1	.	.	271	273	TTC	582	584	TTC	199;198;197	T;T;C	192;191;190	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5858	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3437	170.1	1	SNP	p	D95G	1	.	.	283	285	GGC	594	596	GGC	197;195;196	G;G;C	189;185;187	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5858	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3437	170.1	1	SNP	p	G95N	0	.	.	283	285	GGC	594	596	GGC	197;195;196	G;G;C	189;185;187	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1704	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1231	137.5	1	SNP	p	G45D	0	.	.	133	135	GGC	430	432	GGC	207;209;207	G;G;C	192;184;186	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	880	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1140	76.9	0	.	n	.	0	A197.	DEL	197	197	A	601	601	A	201	A	189	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5972	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2875	206.5	1	SNP	p	D86N	0	.	.	256	258	GAC	542	544	GAC	231;233;232	G;A;C	216;213;217	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5972	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2875	206.5	1	SNP	p	R87W	0	.	.	259	261	CGT	545	547	CGT	234;236;236	C,A,T;G;T	218,1,1;220;216	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5972	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2875	206.5	1	SNP	p	S87R	1	.	.	259	261	CGT	545	547	CGT	234;236;236	C,A,T;G;T	218,1,1;220;216	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5972	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2875	206.5	1	SNP	p	R87I	0	.	.	259	261	CGT	545	547	CGT	234;236;236	C,A,T;G;T	218,1,1;220;216	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5972	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2875	206.5	1	SNP	p	S88P	0	.	.	262	264	TCC	548	550	TCC	236;237;238	T;C;C	219;224;225	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4452	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2648	167.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1562	1564	GGC	233;233;231	G;G;C	215;210;206	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1291	1293	GCC	227;231;232	G;C;C	210;214;216	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1294	1296	ATG	233;234;231	A;T;G	217;218;212	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1306	1308	ACC	234;234;234	A;C;C	215;217;220	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1306	1308	ACC	234;234;234	A;C;C	215;217;220	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1807	1809	ACC	201;199;197	A,C;C;C	178,1;181;182	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1861	1863	GCG	206;207;208	G,A;C;G	194,1;196;197	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1861	1863	GCG	206;207;208	G,A;C;G	194,1;196;197	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1984	1986	GGT	185;183;183	G,C;G;T	171,1;170;170	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1993	1995	AGC	171;169;164	A;G;C	155;155;149	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4088	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2418	168.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2011	2013	CCG	154;158;155	C,G;C;G	116,7;119;122	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6034	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3121	192.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1591	1593	CCG	228;232;232	C;C;G	197;213;201	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2566	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1834	138.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	571	571	C	175	C	163	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3092	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1778	173.0	0	.	p	.	0	I45L	NONSYN	133	135	ATT	570	572	CTT	244;243;242	C;T;T	223;222;223	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3092	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1778	173.0	0	.	p	.	0	G210R	NONSYN	628	630	GGA	1065	1067	AGA	259;257;252	A;G;A	245;242;238	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3092	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1778	173.0	1	SNP	p	G120K	1	.	.	358	360	AAG	795	797	AAG	278;278;276	A;A;G	261;263;257	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3092	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1778	173.0	1	SNP	p	A121N	1	.	.	361	363	AAC	798	800	AAC	272;271;268	A;A;C	253;255;252	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3092	porB1b	1038	1038	99.81	porB1b.l6.c4.ctg.1	1778	173.0	1	SNP	p	N121D	0	.	.	361	363	AAC	798	800	AAC	272;271;268	A;A;C	253;255;252	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11632	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4917	235.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1258	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	890	139.1	1	SNP	p	V57M	1	.	.	169	171	ATG	452	454	ATG	243;242;243	A;T;G	227;226;227	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
